Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
=== Available forms === Tiagabine is available in the form of 2, 4, 5, 10, 12, 15, and 16 mg oral tablets. The drug is taken 1 to 4 times per day due to its short elimination half-life. A sustained-release formulation would be advantageous but has not been developed or marketed.
=== Pharmacodynamics === In rabbits, 2,3-dihydro-LSD had about 4% (1/25th) of the potency of LSD in inducing hyperthermia, while in mice, it was "equally toxic" (presumably referring to LD50Tooltip median lethal dose) as LSD.
=== Risk factors === Risk factors associated with TIA are categorized as modifiable or non-modifiable. Non-modifiable risk factors include age greater than 55, sex, family history, genetics, and race/ethnicity. Modifiable risk factors include cigarette smoking, hypertension (elevated blood pressure), diabetes, hyperlipidemia, level of carotid artery stenosis (asymptomatic or symptomatic) and activity level. The modifiable risk factors are commonly targeted in treatment options to attempt to minimize risk of TIA and stroke.
The chemical nature of the stationary phase. The stationary phase can be coated with some ligands at different bonding densities (how many ligands are bonded per surface area). The composition of the mobile phase. The mobile phase may be made of one solvent, or a mixture of several solvents. The solvents can be mixed at different ratios. Different mobile phases have different properties, such as polarity. When a mobile phase consists of mostly one solvent, with some other solvents added in small amounts, those other solvents are called "mobile phase modifiers". The pH of the mobile phase, which affect the ionization state of the solutes and their polarity. This can be changed with additives such as buffers. Usually, the stationary phase is made of a layer of hydrophobic substrate bonded to the surface of porous silica gel particles. The particles come in various shapes (spheric, irregular), at different diameters (sub-2, 3, 5, 7, 10 μm), with varying pore diameters (60, 100, 150, 300 Å). The particle diameters are often given as mesh numbers. For example, 2500-mesh corresponds to a particle diameter of 5 μm. The hydrophobic substrates are generally alkyl chains, such as C3, C4, C8, C18, or more. The longer the chain, the longer the sample components will be retained. It would make the resolution power higher, but also make the chromatography take longer to run. Most current methods of separation of biomedical materials use C18 columns, sometimes called by trade names, such as ODS (octadecylsilane) or RP-18 (reverse phase 18).
Sources: en.wikipedia.org
While the Leidenfrost temperature is not directly related to the surface tension of the fluid, it is indirectly dependent on it through the film boiling temperature. For fluids with similar thermophysical properties, the one with higher surface tension usually has a higher Leidenfrost temperature. A related phenomenon was observed during the solidification of paraffin wax droplets, which develop a characteristic apple-like shape with a central dimple due to the combined effects of gravity, viscosity increase, and heat conduction through a mushy zone. For example, for a saturated water–copper interface, the Leidenfrost temperature is 257 °C (495 °F). The Leidenfrost temperatures for glycerol and common alcohols are significantly smaller because of their lower surface tension values (density and viscosity differences are also contributing factors.)
It can also cause sexual side effects, galactorrhoea, infertility, gynecomastia, and, with chronic use, reduced bone mineral density leading to breaks, all of which are associated with increased prolactin secretion. Alpha α1 adrenergic receptors: This action accounts for the orthostatic hypotensive effects and perhaps some of the sedating effects of risperidone. Alpha α2 adrenergic receptors: Risperidone's action at these receptors may cause greater positive, negative, affective, and cognitive symptom control. Histamine H1 receptors: effects on these receptors account for its sedation and reduction in vigilance. This may also lead to drowsiness and weight gain. 5-HT2A receptor: Risperidone’s atypicality is relatively strong in terms of its binding preference for 5-HT2A receptors over dopamine D2 receptors. However, clozapine is generally considered stronger in this regard. Clozapine differs in that it has lower overall receptor affinity compared to some other atypical antipsychotics, but still maintains an approximate 4-fold higher affinity for 5-HT2A receptors relative to D2 receptors. Among three atypical antipsychotics often noted for significant 5-HT2A receptor blockade (risperidone, olanzapine, and clozapine), risperidone shows the highest degree of receptor occupancy in a dose-dependent comparison. At approximately 20 mg risperidone and 6 mg olanzapine, reported receptor occupancies are around 93–95%, respectively. Clozapine ranks third when compared using chlorpromazine equivalents.
==== Metabolism ==== Suvorexant is metabolized primarily by hydroxylation via CYP3A enzymes. CYP2C19 also contributes to suvorexant metabolism to a minor extent. The major circulating forms are suvorexant and its metabolite hydroxysuvorexant. The hydroxysuvorexant (M9) metabolite is not expected to be pharmacologically active. It showed 10-fold lower affinity for the orexin receptors than suvorexant in vitro, was a substrate for P-glycoprotein making it unlikely to cross the blood–brain barrier, and did not show sedative effects in animal studies. Suvorexant also has several other minor metabolites.
==== South Korea ==== Mister Donut briefly entered the South Korean market in July 2014 through a franchise agreement with SDK2, owned by local construction company SDK. The contract was terminated due to the SDK violating franchise contracts and "selling products that were not on the brand's official menu". SDK reportedly closed its stores in 2017.
=== Oxidative addition === Oxidative addition to the 14-electron Pd(0) complex is proposed. This process gives a 16-electron Pd(II) species. It has been suggested that anionic ligands, such as OAc, accelerate this step by the formation of [Pd(OAc)(PR3)n]−, making the palladium species more nucleophillic. In some cases, especially when an sp3-hybridized organohalide is used, an SN2 type mechanism tends to prevail, yet this is not as commonly seen in the literature. However, despite normally forming a cis-intermediate after a concerted oxidative addition, this product is in rapid equilibrium with its trans-isomer.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.